Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Sacroiliitis Treatment Market Forecast Highlighting Growth From $1.89 Billion To $2.49 Billion
The market for sacroiliitis treatments has experienced robust expansion recently, with projections indicating continued growth from 1.77 billion dollars in 2025 to 1.9 billion dollars in 2026, marking a compound annual growth rate of 7.4%. This historical upward trend is largely attributable to a rising incidence of inflammatory spinal conditions, the broader application of diagnostic imaging techniques, a deeper comprehension of sacroiliac joint pathologies, the proliferation of pain management facilities, and the accessibility of sophisticated pharmaceutical treatments.
The market dedicated to sacroiliitis treatments is poised for significant expansion over the upcoming years, projecting a value of $2.5 billion by 2030, driven by a compound annual growth rate of 7.1%. This anticipated growth is fueled by several key factors, including a greater uptake of biologic medications, an escalating need for less invasive pain relief alternatives, the proliferation of outpatient orthopedic surgeries, heightened integration of digital diagnostic tools, and an intensified emphasis on restoring long-term mobility. During this forecast period, prominent trends shaping the market include a more frequent application of imaging techniques for diagnosis, increased acceptance of minimally invasive sacroiliac joint fusion procedures, a growing inclination towards biologic and specialized therapies, the expanding use of radiofrequency-based pain management strategies, and a refined focus on tailoring treatment plans to individual patient needs.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24688&type=smp
Sacroiliitis Treatment Market Demand Drivers Creating New Revenue Opportunities
The escalating occurrence of joint conditions is anticipated to be a significant driver for the expansion of the sacroiliitis treatment market. Joint disorders, characterized by pain, inflammation, stiffness, and restricted movement, can stem from injuries, the aging process, autoimmune conditions, or infections. This rise in joint disorders is largely attributed to an aging global population, where natural joint degeneration leads to a greater prevalence of ailments such as osteoarthritis and other degenerative joint diseases. Sacroiliitis treatment offers a beneficial approach to managing these joint disorders by diminishing inflammation and pain within the sacroiliac joints, thereby enhancing mobility and overall joint functionality. This improvement can effectively alleviate symptoms and deter further joint deterioration. Illustrating this trend, as reported by Arthritis Australia in February 2024, osteoarthritis (OA) is forecast to impact 2.35 million Australians in 2025, constituting 57% of all arthritis cases and emerging as the predominant form of arthritis nationwide. Projections indicate a further increase, with the number of Australians affected by OA expected to reach 3.11 million by 2040, marking a 32% surge from the 2025 figures and adding an estimated 762,515 individuals with OA in Australia between 2025 and 2040. Consequently, the growing prevalence of joint disorders is fueling the advancement of the sacroiliitis treatment market.
Sacroiliitis Treatment Market Segmentation: How Is The Market Structured Across Key Categories?
The sacroiliitis treatment market covered in this report is segmented –
1) By Type: Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation, Electrical Stimulation
2) By Diagnosis: Imaging Tests, Physical Examination, Laboratory Tests, Other Diagnosis
3) By Route Of Administration: Oral, Injectable, Topical
4) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Care Settings
Subsegments:
1) By Medications: NSAIDs (Nonsteroidal Anti-Inflammatory Drugs), Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic Agents, Analgesics
2) By Joint Injections: Corticosteroid Injections, Platelet-Rich Plasma (PRP) Injections, Hyaluronic Acid Injections, Prolotherapy
3) By Joint Fusion: Minimally Invasive SI Joint Fusion, Open SI Joint Fusion, Robotic-Assisted Fusion Techniques, Posterior Approach Fusion, Lateral Approach Fusion
4) By Radiofrequency Denervation: Conventional Radiofrequency Ablation, Cooled Radiofrequency Ablation, Pulsed Radiofrequency Ablation
5) By Electrical Stimulation: Transcutaneous Electrical Nerve Stimulation (TENS), Spinal Cord Stimulation (SCS), Peripheral Nerve Stimulation (PNS)
Sacroiliitis Treatment Market Trends Driving Strategic Industry Expansion
To gain a competitive edge in the sacroiliitis treatment sector, leading corporations prioritize securing official endorsements from regulatory bodies, a crucial step for expediting the introduction of novel treatments, facilitating market penetration, and solidifying their standing. These regulatory authorizations signify formal validation by governmental health authorities, confirming a medical intervention’s safety and efficacy for public application. As an illustration, in December 2023, the US-based medical device firm Spinal Simplicity was granted 510(k) clearance by the FDA for its Liberty-SI Lateral Implant System, a specialized, minimally invasive instrument engineered for sacroiliac joint fusion in individuals experiencing issues like sacroiliac disruptions and degenerative sacroiliitis. This innovative system employs a lateral technique, involving the insertion of one or two titanium implants via the ilium, spanning the SI joint into the sacrum to achieve robust stabilization and fusion. The implants, characterized by a central threaded core equipped with expandable wings and compression features, are offered in various dimensions and are treated with a hydroxyapatite coating to promote better biological integration, aiming for a procedure that is both safer and less intrusive, potentially leading to reduced anesthesia duration and enhanced patient results.
Sacroiliitis Treatment Market Competitive Landscape And Leading Companies
Major companies operating in the sacroiliitis treatment market are Pfizer Inc, Johnson And Johnson, AbbVie Inc, Novartis AG, Eli Lilly And Company, Boehringer Ingelheim International GmbH, Amgen Inc, Biogen Inc, Sandoz Group AG, UCB SA, Hikma Pharmaceuticals PLC, Samsung Bioepis Co Ltd, Lupin Limited, Zydus Lifesciences Limited, Celltrion Healthcare Co Ltd, Torrent Pharmaceuticals Limited, Globus Medical, Orthofix Medical Inc, Coherus BioSciences Inc, SI BONE Inc, Medtronic plc
Access The Complete Sacroiliitis Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/sacroiliitis-treatment-global-market-report
Sacroiliitis Treatment Market Regional Analysis: Which Region Leads By Revenue?
North Americawas the largest region in the sacroiliitis treatment market in2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the sacroiliitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
